Q-omics provides the consensus-scored MAMDC2-AS1 profile across patient tissues and cancer cell-line models. MAMDC2-AS1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MAMDC2-AS1 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MAMDC2-AS1 RNA expression shows 18,233 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, KIRC, and THYM as cancer lineages where MAMDC2-AS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAMDC2-AS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAMDC2-AS1 survival associations across molecular data types. MAMDC2-AS1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAMDC2-AS1 RNA expression–survival associations across cancer types. High MAMDC2-AS1 expression shows unfavorable associations in LGG and ESCA, but favorable associations in UCS, LIHC, KIRP and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for MAMDC2-AS1 RNA expression.
This table summarizes MAMDC2-AS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAMDC2-AS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAMDC2-AS1 shows lower tumor expression in KIRC, LUSC, COAD, UCEC, KICH and LUAD. The KIRC box plot shows higher MAMDC2-AS1 RNA expression in normal versus tumor tissue (log2 FC = −0.266, t-test p < 0.001).
This table shows molecular features associated with MAMDC2-AS1 in patient tissues and cancer cell lines. In patient samples, MAMDC2-AS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
